🧬 GENETIC RESEARCH
Synthetic Immunity: The End of Seasonal Viruses?
"We are no longer just treating symptoms; we are re-coding the human defense architecture."
Phase
Clinical III
Success Rate
98.4%
A groundbreaking study published this morning confirms that the newly developed programmable mRNA platform provides lifelong protection against respiratory mutations.
Read Full Scientific Paper ➔